Nev. Admin. Code § 639.Sec. 4.2

Current through December 12, 2024

Section 639.Sec. 4.2 - NEW

1. Except as otherwise provided in subsection 2 of section 6 of this regulation, a pharmacist shall, before prescribing, dispensing or administering a preexposure prophylaxis drug pursuant to section 1 of Senate Bill No. 325, chapter 492, Statutes of Nevada 2021, at page 3201 (NRS 639.28085), complete an assessment of the patient that includes, without limitation:

(a) A test for human immunodeficiency virus;

(b) A test for renal function;

(c) A test for hepatitis B; and

(d) An evaluation for any signs and symptoms of acute human immunodeficiency virus infection.

2. A pharmacist may prescribe, dispense or administer a postexposure prophylaxis drug pursuant to section 1 of Senate Bill No. 325, chapter 492, Statutes of Nevada 2021, at page 3201 (NRS 639.28085), immediately upon the request of a patient who has recently been exposed to human immunodeficiency virus. Except as otherwise provided in subsection 2 of section 6 of this regulation, the pharmacist shall, before continuation of treatment using such drugs beyond the initial prescribing, dispensing or administering, complete an assessment of the patient that includes, without limitation:

(a) A test for human immunodeficiency virus;

(b) A pregnancy test if the patient is a woman of child-bearing age;

(c) A test for liver function;

(d) A test for renal function;

(e) A test and screening for sexually transmitted infections;

(f) A test for hepatitis B; and

(g) A test for hepatitis C.

3. Upon prescribing, dispensing or administering a preexposure prophylaxis drug or a postexposure prophylaxis drug pursuant to section 1 of Senate Bill No. 325, chapter 492, Statutes of Nevada 2021, at page 3201 (NRS 639.28085), a pharmacist shall counsel the patient and provide information on the drug dispensed or administered, including, without limitation:

(a) The proper administration and storage of the drug;

(b) The proper dosage of the drug;

(c) The effectiveness of the drug;

(d) The potential side effects of the drug;

(e) The need to be regularly tested for human immunodeficiency virus;

(f) The need to adhere to the treatment; and

(g) If applicable, the inability of the drug to prevent sexually transmitted infections other than human immunodeficiency virus.

4. As used in this section:

(a) "Postexposure prophylaxis drug" means a drug approved by the United States Food and Drug Administration for preventing the acquisition of human immunodeficiency virus that is designed to be administered after exposure to the virus.

(b) "Preexposure prophylaxis drug" means a drug approved by the United States Food and Drug Administration for preventing the acquisition of human immunodeficiency virus that is designed to be administered before exposure to the virus.

Nev. Admin. Code § 639.Sec. 4.2

Added to NAC by Bd. of Pharmacy by R039-21A, eff. 4/11/2022

NRS 639.070, section 1 of Senate Bill No. 325, chapter 492, Statutes of Nevada 2021, at page 3201 (NRS 639.28085)